Trends in annual price for disease-modifying therapies for multiple sclerosis; 1993 to 2023

**Self-administered Injections**

- **Betaseron (Bayer)**: 7.1% $119,610
- **Avonex (Biogen)**: 5.5% $101,796
- **Rebif (EMD Serono)**: 4.0% $119,973
- **Extavia (Novartis)**: 15.4% $93,566
- **Plegridy (Biogen)**: 5.5% $101,796
- **Kesimpta (Novartis)**: 9.1% $97,969

**Glatiramer Acetate**

- **Copaxone 20 (Teva)**: 0.0% $86,554
- **Copaxone 40 (Teva)**: 0.0% $75,816
- **Glatopa (Sandoz)**: 0.0% $18,250
- **Glat Acet (Mylan)**: 0.0% $23,725
- **Glat Acet 40 (Mylan)**: 0.0% $25,350

**S1P Receptor Modulators**

- **Gilenya (Novartis)**: 9.1% $126,812
- **Mayzent (Novartis)**: 9.1% $112,346
- **Zeposia (Celgene)**: 6.0% $99,549
- **Ponvory (Janssen)**: 0.0% $103,660

**Fumarates**

- **Tecfidera (Biogen)**: 8.1% $108,896
- **Vumerity (Biogen)**: 4.0% $98,064
- **Bafiertam (Banner)**: 5.0% $76,192
- **Dimethyl fumarate (generic)**: 0.0% $2,738

**Other Oral DMTs**

- **Aubagio (Genzyme)**: 6.0% $109,862
- **Mavenclad (EMD Serono)**: 6.0% $127,986

**Infusions**

- **Tysabri (Biogen)**: 4.5% $106,722
- **Lemtrada (Genzyme)**: 4.7% $92,496
- **Ocrevus (Genentech)**: 5.5% $75,102
- **Brumvi (TG Therapeutics)**: NA $59,000

Notes: Annual price estimated from wholesale acquisition costs (First Databank)
Market entrance date in parenthesis
Dashed line is projected annual price of Betaseron assuming only inflationary increases in price (CPI)
Lemtrada is based on four 12 mg vials (Package insert dosing: 12 mg/day (5 vials) for five consecutive days in first year; 12 mg/day (3 vials) for three days in year 2);
Brumvi is based on maintenance dose of 450 mg (3 vials) twice a year;
*2021 to 2022 (January); **Generic, lowest WAC reported